Shameer Khader; Youyi Zhang; Daniel Jackson; Kirsty Rhodes; Imran Khan Anwer Neelufer; Sreenath Nampally; Andrzej Prokop; Emmette Hutchison; Jiabu Ye; Feng Liu; Antony Sabin; James Weatherall; Cristina Duran; Renee Iacona; Faisal Khan; Pralay Mukhopadhyay, PhD; Applying Advanced Data Analysis to Immunotherapy Drug Discovery for Uveal Melanoma. Anna K. Kozlowska, PhD; Yan Zhang, PhD; Jacqueline Fritz, BS; Steven Wang, PhD; Rebecca A. Codde, BS; Elvira Argus, PhD; Samad A. Ibitokou, PhD; Vanitra Richardson, MS; Sumiti Jain, PhD; Maximilian Richter, PhD; Deepak Patil, PhD; Yening Tan, MS; Min Tong, MS; Lu Yao, PhD; Majid Ghoddusi, PhD; Eric M. Ostertag, MD, PhD; Julia Coronella, PhD; Devon J. Shedlock, PhD; Adoptive immunotherapy; CAR T cells; Solid tumors; T cell, Guanylyl cyclase C as a target for CAR-T cell therapy in a metastatic gastric cancer model. Matthew J. Frigault, MD, MSc; Megan Cartwright, PhD; Krista Marcello, BA; Timothy A. Quill, PhD; Daniel J. DeAngelo, MD, PhD; Ilene A. Galinsky, NP; Shilpa Paul, PharmD, BCOP; Jae H. Park, MD; Matthew J. Frigault, MD, MSc; CAR T cells; Cytokine; Immune toxicity; Leukemia/Lymphoma, Time to diagnostic clarity for suspected checkpoint-inhibitor pneumonitis in patients with lung cancer. Matthew P. Rausch, PhD; Devapregasan Moodley, PhD; Marisa O. Peluso, MS; Secil Koseoglu, PhD; Jing Hua, MD, MS; Gege Tan, MA; Ricard Masia, MD PhD; Benjamin H. Lee, MD PhD; Isabelle Cousineau, PhD; Simon Turcotte, MD MSc; John Stagg, PhD; Vito J. Palombella, PhD; Pamela M. Holland, PhD; Jonathan A. Hill, PhD; Antibody; Cytokine; Immune suppression; Myeloid cells; Tumor evasion, Antibiotics and response to immunotherapy: Real-world experience. Shrutii Sarda, PhD; David Merrill, PhD; Heesun Shin; Anna McGeachy, PhD; Birgit Drews; Wing Lee; Rajesh K. Gottimukkala, MS; Janice K. Au-Young, PhD; Fiona Hyland; Shrutii Sarda, PhD; Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors. Kinjal Parikh, PharmD, BCOP; Kinjal Parikh, PharmD, BCOP; Kinjal Parikh, PharmD, BCOP; Charlotte Warren; Emily Van Laar, MS; Jason J. Luke, MD; An immuno-oncology census: assessment of clinician knowledge and educational needs in 2020. Aaron J. Morris, PhD; Evan D. Walters; Bassel Akache; Michael J. McCluskie; Arthur M. Krieg, MD; Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models. Joseph M. Eckenrode, PhD; Omar F. Laterza, PhD; Michael E. Lassman, PhD; Biomarkers; Proteomics; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs), Spatial Heterogeneity of Tumor Associated Macrophages in the Tumor Immune Microenvironment in ccRCC. Intralesional injection of rose bengal improves the efficacy of gemcitabine chemotherapy against pancreatic cancer. ; Qianchuan He; Yuzheng Zhang; Lee Cranmer; Elizabeth T. Loggers; Sabrina McDonnell; Shannon Maxwell; Seth M. Pollack, MD; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Monocyte/Macrophage; T cell, Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel). Lino E. Torres-Dominguez, PhD; Lina S. Franco, PhD; Mario Abrantes; Benjamin S. Walker; Zachary Tacner; Cassandra Kien; Natalie M. Elliott; Anna K. Waters; Grant McFadden, PhD; Steven J. Potts, PhD; Leslie L. Sharp, PhD; Checkpoint blockade; Costimulation; Gene expression; Immune adjuvant; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment, In situ vaccination with oncolytic vesicular stomatitis virus improves anti-tumor immune response and outcome in bladder cancer. Maria Jose Costa, PhD; Ryan Stafford, PhD; Zhiqiang Ku, PhD; Jing-Tyan Ma; Krista McCutcheon; Xiaoye Liu, PhD; Heyu Chen, PhD; Kyu Hong; Tao Huang, PhD; Ningyan Zhang, PhD; Zhiqiang An, PhD; Cheng Cheng Zhang, PhD; X. Charlene Liao, PhD; An Song, PhD; Antibody; Antigen presenting cells; Checkpoint blockade; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor evasion; Tumor microenvironment, Enhancement of anti-tumor immunity by ICT01: a novel g9d2 T cell-activating antibody targeting Butyrophilin-3A (BTN3A). Yeung, MD; B cell; Biomarkers; CAR T cells; Clinical study; Cytokine; Immune toxicity; Leukemia/Lymphoma; T cell, Ocular adverse events associated with Programmed Death-1 and Programmed Death Ligand-1 immunotherapy. Anna S. Herbstritt, MS; Elfriede Noessner, Prof. Dr.; Petra U. Prinz, Dr.; Mani D. Kadiyala, BS; Melissa Maxwell, MS; Dingxue Yan, PhD; James Cardia, PhD; Simon P. Fricker, PhD; Adoptive immunotherapy; NK/NK T cell; RNA; Solid tumors; T cell; Tumor evasion, In Vitro Anticancer and Immunomodulatory Activities of NBT-167, a Dimer of Resveratrol. Mark Lythgoe, MBBS, MRPharmS; Justin Stebbing; Emily Pickford; Axel Glasmacher; Marsilio Adriani, PhD; Gayle L. Fyvie; Adam Frampton; Alex Stevenson; Jonathan Krell, PhD, MRCP, MBChB, BSc; Clinical study; Clinical trial; Microbiome; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR, Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer. An; Cunxiang Ju; Henry Q. Li; Davy X. Ouyang, PhD; Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors. John A. Ligon, MD; Woonyoung Choi; Gady Cojocaru; Wei Fu; Emily H. Hsiue, MD; Teniola F. Oke; Carol D. Morris; Adam Levin; Daniel S. Rhee; David J. McConkey; Robert A. Anders, MD, PhD; Drew M. Pardoll, MD, PhD; Nicolas J. Llosa, MD; Checkpoint blockade; Chemokine; Cytokine; Myeloid cells; MDSC; Solid tumors; Tumor microenvironment, High dimensional flow cytometry analysis in newly diagnosed acute myeloid leukemia predicts patients outcomes. Son but est double. Adnan Nagrial, MD; Sumayah Jamal, MD-PhD; Anthony M. Joshua, MD; Richard W. Eek, MD; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment, A Phase II study of the anti-programmed cell death-1 (PD-1) antibody Penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy. Geoffrey T. Gibney, MD; Joanne Xiu; Gino K. In, MD, MPH; Steven J. O'Day, MD; Jose Lutzky, MD, FACP; Joseph J. Drabick, MD, FACP, FIDSA; Ari M. VanderWalde, MD, MPH, MBioeth; Kelsey Poorman; W. M. Korn; Michael B. Atkins, MD; Angiogenesis; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment, Immune cell profiling across solid tumor types by mass cytometry reveals tumor enrichment of PD-1+/LAG-3+ CD8 memory T cells that exhibit tumor-reactive yet dysfunctional features. Lucas A. Horn, PhD; Linjie Tian, PhD; Dallas B. Iwamoto, PhD; Christopher C. Paustian, PhD; Adi Mehta, PhD; Fridtjof Lund-Johansen, MD, PhD; Rachel E. Sanborn, MD; Bryan R. Bell, MD, DDS, FACS; Madeleine Laws, BS; Glenna McDonnell, MS; Yoshinobu Koguchi, MD, PhD; Carlo B. Bifulco, MD; Brian D. Piening, PhD; Carmen Ballesteros Merino, PhD; Shawn M. Jensen, PhD; Takashi Shimada, PhD; Hong-Ming Hu, PhD; Walter J. Urba, MD, PhD; Rom S. Leidner, MD; Marcus A. Couey, MD, DDS; Antibody; Clinical study; Clinical trial; Costimulation; Neoantigens; Solid tumors; Surfaceome; T cell; Tumor antigens; Vaccine, MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. Pablo Fernandez-Penas, MD, PhD; Matteo S. Carlino, M.D., Ph.D.; Katy K. Tsai, MD; Victoria G. Atkinson, MD; Monaster Shaheen, MD; Sajeve Thomas, MD; Catalin Mihalcioiu, MD, FRCP; Tom Van Hagen, MD; Rachel Roberts-Thomson, MD; Andrew Haydon, M.D., Ph.D.; Andrew Mant, MD; Marcus O. Butler, MD; Gregory A. Daniels, MD, PhD; Elizabeth I. Buchbinder, MD; John Hyngstrom, MD; Mecker Moller, MD, FACS; Igor Puzanov, MD, MSCI; C. Lance Cowey, MD; Eric D. Whitman, MD, FACS; Carmen Ballesteros-Merino, PhD; Shawn M. Jensen, PhD; Bernard A. Yasunori Amaishi; Yu Okubo, PhD; Yizheng Wang; Linan Wang, PhD; Takuma Kato, PhD; Sachiko Okamoto, PhD; Hiroshi Shiku, PhD; Junichi Mineno, PhD; CAR T cells; Solid tumors; T cell; Tumor antigens, Drug-regulatable engineered T cells eliminate CD33+ and CD33ΔE2+ AML. Jifang Gong, MD; Lin Shen, MD,PhD; Jifang Gong, MD; Zhi Dong; Dan Liu; June Xu; Jing Yang; Yue Yang; Yakun Qi; Jie Men; Paul Kong; Ting Xu; Bispecifics; Checkpoint blockade; Solid tumors, Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer. Smits; Antibody; Antigen presenting cells; Cytokine; Dendritic cell; NK/NKT cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs), Oncolytic Parainfluenza Virus 5 Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in 2D and 3D spheroid cultures. Yannick S. Rakké, MD, MSc; Yannick S. Rakké, MD, MSc; Lucia Campos Carrascosa, PhD; Adriaan A. van Beek, PhD; Valeska de Ruiter, MSc; Michael Doukas, MD, PhD; Susan ter Borg, MD; Pascal G. Doornebosch, MD, PhD; Maarten Vermaas, MD, PhD; Erwin van der Harst, MD, PhD; Peter Paul LO. Hongjuan Zhang, PhD; Jun Zhou; Shuang Zhu; Jia Zheng; Limei Shang; Chunmei Li; Xuefei Yan, PhD; Rui Zhang; Mingfa Zang; Annie Xiaoyu An; Xiaoxi Xu; Shuzong Wang; Henry Q. Li; Yujun Huang; Bispecifics; CAR T cells; Checkpoint blockade; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment, Sexual dimorphism in myeloid-derived suppressor cells promote GBM progression in females via IL-1b. Charles J. Schneider, MD, FACP; Michael Krainock, MD; Meenakshi Malhotra; Paul Billings, MD, PhD; Alexey Aleshin, MD, MBA; Bioinformatics; Biomarkers; Chemotherapy; Immune adjuvant; Solid tumors, The role of ligands of activatory receptor NKG2D in the immune-dependent pathogenesis and evolution of inflammatory bowel disease (IBD). Anne-Laure Blayo; Laurène Deshons; Alexia Dumont; Christel Franchet; Célia Halter; Ludovic Herbin; Gaël Hommet; Stanislas Mayer; Alban Bessede; Imane Nafia; Marjorie Sidhoum; Xavier Leroy; Stéphan Schann; Biomarkers; Checkpoint blockade; Immune suppression; Solid tumors; Tumor microenvironment, Synergistic cancer immunotherapy using tumor tissue-derived exosomes and artificially produced bacterial outer membrane vesicles. Anna Juncker-Jensen, PhD; Gang Huang; Mate L. Nagy; Xin Lu; Anna Juncker-Jensen, PhD; Anna Juncker-Jensen, PhD; Adoptive immunotherapy; B cell; Immune contexture; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma, Activation of NK T cells promote the inflammatory tumor microenvironment and control the growth of solid tumor. ; Janice M. Mehnert, M.D. Michael J. Wagner, M.D. Price, MBBS, DHlthSc (Medicine), FRACP; Sant P. Chawla, MD; Gerald S. Falchook, MD, MS; Hans Prenen, MD; Iwona Lugowska; Vivek Subbiah, MD; Jose Monzon; Yuichi Ozawa; Tobias Arkenau, MD, PhD; Caio S. Rocha Lima, MD; Yasutoshi Kuboki; Tomohiro Nishina; Mun Hui; Erik Rasmussen, PhD; Hansen Wong; Saltanat Najmi; Nooshin H. Sadraei; Antibody; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Solid tumors, ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC). D; Daniel C. Rose, BS in biology; Saul Kivimae, PhD; Werner Rubas, PhD; William L. Redmond, Ph.D.; Cytokine; NK/NK T cell; Radiotherapy; TLR; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment, Combination treatment using KISIMATM protein-based cancer vaccine and systemic STING agonist results in profound modulation of tumor microenvironment and improved tumor control. Yu-Lin Su, PhD; Marcin Kortylewski, PhD; Priyanka Duttagupta, PhD; Antigen presenting cells; Bispecifics; Immune suppression; Leukemia/Lymphoma; MDSC; Monocyte/Macrophage; Myeloid cells; RNA; Targeted therapy; TLR, Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy. Evisa Gjini, PhD; Jimena Trillo-tinoco; Andrew Browne; Ryan Powles; Tai Wang; Christine Tauras; Ana Lako; Ruben Ferrer-Luna; Zoe Bleicher; timothy consedine; Chensheng Zhou; Evan Kelemen; anne lewin; Catherine King; sumit bhattacharya; harris bell-temin; ashok dongre; David Nelson; Christos Hatzis, PhD; Kenzie Macisaac; Fadi Towfic; Benjamin Chen, MD, PhD; Michaela Bowden, PhD; Evisa Gjini, PhD; Biomarkers; Gene expression; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma. Lajos Pusztai, MD; Hailing Lu, MD, PhD; Christopher Hale, PhD; Anne Grosse-Wilde, PhD; Jennifer Specht, MD; Shanu Modi, MD; Hyo Han, MD; Javier Cortes, MD PhD; Mafalda Oliveira, MD, PhD; Phillip Garfin, MD, PhD; Zejing Wang, MD, PhD; Matthew Onsum, PhD; Antibody; Biomarkers; Checkpoint blockade; Immune monitoring; Monocyte/Macrophage; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment. ; Bethany Nagy, BS; Cristina Bergamaschi, PhD; Barbara K. Felber, PhD; George N. Pavlakis, M.D., Ph.D.; Antigen presenting cells; Cytokine; Dendritic cell; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment, NL-201, a de novo IL-2 and IL-15 agonist, demonstrates enhanced in vivo antitumor activity in combination with multiple cancer immunotherapies. Ayana Ruffin, MS; Anthony R. Cillo, PhD; Tracy Tabib; Angen Liu; Sayali Onkar; Sheryl R. Kunning; Caleb Lampenfeld, B.S. ; Ashley Weaver; Sandip P. Patel, MD; Incidence and risk factors for stroke associated with immune checkpoint inhibitor therapy in cancer patients using real-world clinical data. Bhumsuk Keam, MD, PhD; Tae Min Kim, MD, PhD; Do-Youn Oh, MD, PhD; Chan-Young Ock, MD, PhD; Won Ki Kang, MD, PhD; Yeon Hee Park, MD, PhD; Jeeyun Lee, MD, PhD; Ji Hye Lee, MD; Yun Jeong Song, MD; Young Suk Park, MD, PhD; Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell. Primer on Tumor Immunology and Cancer Immunotherapy™, Workshop on Engineering Immune Cells for Cancer Therapy, Journal for ImmunoTherapy of Cancer Best Paper Awards, Biomarkers, Immune Monitoring, and Novel Technologies, Biomarkers, Immune Monitoring and Novel Technologies, Machine Learning, Artificial Intelligence and Computational Modeling, Machine Learning, Artificial Intelligence, and Computational Modeling, Microbiome and other environmental factors, Regulatory - Financial - and Access Considerations, Tumour associated macrophages in HPV-related carcinoma with adenoid cystic like features of the sinonasal tract; a review of three cases. Sojin Lee, Dr.; Joon Young Park; Goo-Young Kim, Ph.D.; Sang Woo Jo; Minhyuk Yun; Hye Yeong Nam; Helen Cho; RNA; Solid tumors; T cell; Tumor antigens; Vaccine, Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure. Timothy A. Yap, MD, PhD; Mallika Dhawan; Andrew E. Hendifar; Michele Maio, MD; Taofeek K. Owonikoko; Miguel Quintela-Fandino; Ronnie Shapira-Frommer, MD; Sanatan Saraf, MD; Ping Qiu, PhD; Fan Jin, MD; Alexander Gozman; Douglas A. Levine; Antibody; Checkpoint blockade; Clinical trial; Gene expression; Solid tumors; Targeted therapy, Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine. Sarina A. Piha-Paul, MD; Alexander N. Starodub, MD; Raghad Karim, MD; Michael Shafique, MD; Gabriel R. Tinoco Suarez, MD; Curtis Ruegg, PhD; Victoria Smith, PhD; Patrick Chun, MD; Bispecifics; Clinical study; Clinical trial; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor microenvironment, Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2. Burcu Yigit, PhD; Xavier Michelet, PhD; Shalu S. Kharkwal; Eleni Chantzoura, PhD; Jan Bergmann; Alvaro Sebastian Yague, Ph.D; Simon Yue; Darrian Moskowitz; Benjamin Wolf, PhD; Mark A. Exley, PhD; Dhan Chand, PhD; Marc A. Ce livre d’histoires s’adresse aux enfants de plus de “8 ans”. Distinct immune signatures predicting clinical response to PD-1 blockade therapy in gynecological cancers revealed by high-dimensional immune profiling. Melanie Salvermoser; Maria Gerget; Franziska Hasselmann; Elfriede Noessner, Prof. Dr.; Christian Ellinger, Dr. Rer. Marcella Willemsen, MSc; Jenny Bulgarelli; Sudhir C. Kumar; Massimo Guidoboni, MD; John A. Kyte; Irwin Davidson; Rosalie M. Luiten; Checkpoint blockade; T cell; Tumor antigens; Tumor evasion; Tumor microenvironment, The epigenomic landscape of human glioma-associated myeloid cells. Hannah Egan, BSC; Niamh A. Leonard, MSc; Kevin Lynch, PhD; Oliver Treacy, PhD; Amir Nader; Margaret Sheehan, Dr; Sean Hynes, Dr; Laurence J. Egan, MD; Thomas Ritter, Prof.; John Daly; Aisling Hogan, Dr.; Michael O; Aideen E. Ryan, PhD; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma, Distinct genomic features across cytolytic subgroups in skin melanoma. Carlo B. Bifulco, MD; Roshanthi Weerasinghe; Bela Bapat; Alexa K. Dowdell; Shwetha Pindikuri; Sheila Reynolds; Nancy Biery; David Ball; Mary Campbell; Thomas R. Ward; Alisha Stein; Brock E. Schroeder; David A. Eberhard, MD PhD; Brian D. Piening; Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors, Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity. Yanrui Song; Jessie J. Wang; Likun Zhang; Annie X. Saba S. Shaikh, MD; Yan Zang, MS; Hong Wang, PhD; Xi Yang, BS; Cindy Sander; Amy Rose; Diwakar Davar, MD; Jason J. Luke, MD; Hassane M. Zarour, MD; John M. Kirkwood, MD; Greg M. Delgoffe, PhD; Yana G. Najjar, MD; Angiogenesis; Checkpoint blockade; Clinical trial; Metabolism; Solid tumors; Targeted therapy; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment, Rational Sequencing of Immune-Oncology Therapies Achieves Durable Response and Immunologic Memory. Diwakar Davar, MD; Arivarasan Karunamurthy; Douglas Hartman; Richelle DeBlasio, B.Sc. Stephen Chenard, BScH; Stephen Chenard, BScH; Chelsea Jackson, PhD; Thiago Vidotto, MSc, PhD; Celine Hardy, BScH; Tamara Jamaspishvilli, MD, PhD; David Berman, MD, PhD; David Robert Siemens, MD; Madhuri Koti, DVM, MVSc, PhD; B cell; Biomarkers; Gene expression; Immune contexture; Immune suppression; Monocyte/Macrophage; Tumor microenvironment; Tumor stroma. Pierre-Alain Bandinelli, MSc; Julie Cervesi; Clément Le Bescop; Renaud Buffet; Jean De Gunzburg; Gérard Zalcman; Pierre-Alain Bandinelli; Autoimmunity; Checkpoint blockade; Microbiome; Solid tumors, Identification of microbial-derived HLA-bound peptides in melanoma. ; Guy T. Clifton, MD; Timothy J. Vreeland, BS MD; Lexy M. Adams, MD, MPH; Patrick M. McCarthy, MD; Phillip M. Kemp Bohan, MD; Annelies T. Hickeron, MD; John W. Myers, MD; Jessica L. Cindass, MD; Tommy A. Thomas F. Gajewski, MD, PhD; Emily Higgs, BA; Shuyin Li, PhD; Shuyin Li, PhD; Blake Flood, BS; Ken Hatogai; Identification of lung cancer mutational signatures and tumor drivers associated with specific bimodal PD-L1/TMB status.